Evidence map›Paper›PMID 42006819›Full record

ArticleRSC advances2026

pH-responsive Ni-MOF based nanocarriers with folic acid targeting for enhanced chemotherapeutic efficacy in breast cancer.

Komal Zaman Khan, Ammar Saleem, Eman Fayad, Aurang Zaib, Ghazanfar Abbas, Dalal Nasser Binjawhar, Ali Junaid, Muhammad Naeem Ashiq, Zahid Shafiq, Hua-Li Qin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Komal Zaman KhanSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology Wuhan 430070 China qinhuali@whut.edu.cn.
Ammar SaleemSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology Wuhan 430070 China qinhuali@whut.edu.cn.ORCID https://orcid.org/0000-0003-0083-2432
Eman FayadDepartment of Biotechnology, College of Science, Taif University P.O. Box 11099 Taif 21944 Saudi Arabia.
Aurang ZaibSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology Wuhan 430070 China qinhuali@whut.edu.cn.
Ghazanfar AbbasSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology Wuhan 430070 China qinhuali@whut.edu.cn.
Dalal Nasser BinjawharDepartment of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University P.O. Box 84428 Riyadh 11671 Saudi Arabia.
Ali JunaidInstitute of Chemical Sciences, Bahauddin Zakariya University Multan-60800 Pakistan zahidshafiq@bzu.edu.pk.
Muhammad Naeem AshiqInstitute of Chemical Sciences, Bahauddin Zakariya University Multan-60800 Pakistan zahidshafiq@bzu.edu.pk.ORCID https://orcid.org/0000-0001-8561-3065
Zahid ShafiqInstitute of Chemical Sciences, Bahauddin Zakariya University Multan-60800 Pakistan zahidshafiq@bzu.edu.pk.ORCID https://orcid.org/0000-0003-4088-8297
Hua-Li QinSchool of Chemistry, Chemical Engineering and Life Sciences, Wuhan University of Technology Wuhan 430070 China qinhuali@whut.edu.cn.ORCID https://orcid.org/0000-0002-6609-0083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is among the most prevalent malignancies affecting women globally. Conventional chemotherapeutic treatments like 5-fluorouracil (5-FU) are not very effective and can cause serious side effects. To address these challenges, we developed a folic acid-functionalized nickel-based metal-organic framework incorporated with 5-fluorouracil (FA/Ni-MOF/5-FU) as a targeted and pH-responsive nanocarrier for selective breast cancer treatment. The addition of folic acid (FA) made it possible to actively target folate receptors, which are found in high amounts on MDA-MB-231 breast cancer cells. The Ni-MOF acted as biocompatible carrier for controlled drug release.

Identifiers

PMID42006819
PMCPMC13089678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.